The increase was primarily attributable to growth in the CRDMO’s number of customers and projects, driven by antibody-drug conjugates and the broader bioconjugate market.
The certification adds multiplex protein biomarker analysis to the CRDMO’s human-relevant testing capabilities for topical and transdermal drug development.
